IRadimed Corporation
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-77.7% vs price
Base Case (Median)
-72.4% vs price
Bull Case (75th pct.)
-54.8% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $10.18 | -88.3% | High (40%) |
| PE Comparable | $39.85 | -54.4% | Medium (25%) |
| Growth Trajectory DCF | $60.79 | -30.4% | Medium (20%) |
| Graham Number | $17.31 | -80.2% | Medium (40%) |
| EV/EBITDA | $24.16 | -72.4% | Medium (20%) |
| EV/FCF | $39.19 | -55.2% | Medium (20%) |
| Earnings Power Value | $21.76 | -75.1% | Medium (50%) |
Based on 7 out of 8 methods, IRMD appears overvalued at the current price of $87.40. The base case fair value of $24.16 implies 72.4% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.